Skip to main content

Peer Review reports

From: Pyrotinib combined with thalidomide in advanced non-small-cell lung cancer patients harboring HER2 exon 20 insertions (PRIDE): protocol of an open-label, single-arm phase II trial

Original Submission
2 Feb 2021 Submitted Original manuscript
2 Jul 2021 Reviewed Reviewer Report - christos chouaid
15 Aug 2021 Reviewed Reviewer Report
25 Aug 2021 Author responded Author comments - Xinghao Ai
Resubmission - Version 2
25 Aug 2021 Submitted Manuscript version 2
3 Sep 2021 Author responded Author comments - Xinghao Ai
Resubmission - Version 3
3 Sep 2021 Submitted Manuscript version 3
Publishing
6 Sep 2021 Editorially accepted
16 Sep 2021 Article published 10.1186/s12885-021-08759-8

You can find further information about peer review here.

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us